# Safety and Efficacy of the Extracorporeal Liver Assist Device (ELAD®) In Patients With Fulminant Hepatic Failure (FHF)

> **NCT00832728** · PHASE2 · WITHDRAWN · sponsor: **Vital Therapies, Inc.**

## Conditions studied

- Fulminant Hepatic Failure

## Interventions

- **OTHER:** Standard of Care
- **DEVICE:** ELAD®

## Key facts

- **NCT ID:** NCT00832728
- **Lead sponsor:** Vital Therapies, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2009-03
- **Primary completion:** 2011-09
- **Final completion:** 2011-09
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** To focus on another clinical indication.
- **Last updated:** 2012-07-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00832728

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00832728, "Safety and Efficacy of the Extracorporeal Liver Assist Device (ELAD®) In Patients With Fulminant Hepatic Failure (FHF)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00832728. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*